Wayne Kuznar
Wayne Kuznar is a contributor to Urology Times.
Researchers characterize post-sling incontinence
Stress-incontinent women whose urinary urgency incontinence worsens following a sling procedure are a heterogeneous group, according to research presented at the AUA annual meeting in San Diego.
Technology doesn’t raise overall PCa therapy rate
The rate of therapy for localized prostate cancer does not rise in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Efficacy of androgen receptor blockade in castration-resistant prostate Ca not dependent on age
Older men with metastatic castration-resistant prostate cancer (mCRPC) derive a similar if not superior survival benefit from treatment with enzalutamide as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Little survival difference seen with kidney cancer agent
Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase 3 clinical trial.
Metastatic renal cell carcinoma agent nearly doubles survival
A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Ischemic priapism: Immediate prosthesis insertion key
Immediate insertion of a penile prosthesis as a treatment for acute refractory ischemic priapism resolves the acute episode of ischemic penile pain and treats the inevitable erectile dysfunction, according to a recent study.
PSA detects clinically important cancers in older men
More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.
Advanced prostate cancer agent efficacious regardless of age
Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Surveillance called 'reasonable' for small renal masses
Active surveillance appears to be a reasonable option for older patients with small renal masses, most of which are discovered during imaging for unrelated conditions, says the author of a recent study.
IPP placement post-T-shunt surgery appears efficacious
Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.

Poll

View Results